<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A high percentage of colorectal <z:mp ids='MP_0002038'>carcinomas</z:mp> overexpress a lot of growth factors and their receptors, including fibroblast growth factor (FGF) and FGF receptor (FGFR) </plain></SENT>
<SENT sid="1" pm="."><plain>We previously reported that FGFR2 overexpression was associated with distant <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> and that FGFR2 inhibition suppressed cell growth, migration, and invasion </plain></SENT>
<SENT sid="2" pm="."><plain>The FGFR2 splicing isoform FGFR2IIIb is associated with well-differentiated histologic type, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mpath ids='MPATH_177'>angiogenesis</z:mpath>, and <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> to extracellular matrices </plain></SENT>
<SENT sid="3" pm="."><plain>Another isoform, FGFR2IIIc, correlates with the <z:hpo ids='HP_0000718'>aggressiveness</z:hpo> of various types of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>In the present study, we examined the expression and roles of FGFR2IIIc in colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> to determine the effectiveness of FGFR2IIIc-targeting therapy </plain></SENT>
<SENT sid="5" pm="."><plain>In <z:mpath ids='MPATH_458'>normal</z:mpath> colorectal tissues, FGFR2IIIc expression was weakly detected in superficial colorectal epithelial cells and was not detected in proliferative zone cells </plain></SENT>
<SENT sid="6" pm="."><plain>FGFR2IIIc-positive cells were detected by immunohistochemistry in the following lesions, listed in the order of increasing percentage: <z:mpath ids='MPATH_140'>hyperplastic polyps</z:mpath> &lt; low-grade <z:mpath ids='MPATH_270'>adenomas</z:mpath> &lt; high-grade <z:mpath ids='MPATH_270'>adenomas</z:mpath> &lt; <z:mp ids='MP_0002038'>carcinomas</z:mp> </plain></SENT>
<SENT sid="7" pm="."><plain>FGFR2IIIc immunoreactivity was expressed in 27% of colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> cases, and this expression correlated with distant <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> and poor prognosis </plain></SENT>
<SENT sid="8" pm="."><plain>FGFR2IIIc-transfected colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> cells showed increased cell growth, soft agar colony formation, migration, and invasion, as well as decreased <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> to extracellular matrices </plain></SENT>
<SENT sid="9" pm="."><plain>Furthermore, FGFR2IIIc-transfected colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> cells formed larger <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> in subcutaneous tissues and the cecum of <z:mp ids='MP_0003815'>nude</z:mp> mice </plain></SENT>
<SENT sid="10" pm="."><plain>Fully human anti-FGFR2IIIc monoclonal antibody inhibited the growth and migration of colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> cells through alterations in cell migration, cell <z:hpo ids='HP_0011420'>death</z:hpo>, and development-related genes </plain></SENT>
<SENT sid="11" pm="."><plain>In conclusion, FGFR2IIIc plays an important role in colorectal <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> and <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumor progression</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>Monoclonal antibody against FGFR2IIIc has promising potential in colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> therapy </plain></SENT>
</text></document>